Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Trade Show

Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th

Cortexyme, Inc. (Nasdaq: CRTX) announced that it will participate at the 14th Clinical Trials on Alzheimer's Disease Conference (CTAD 2021) as a part of the meeting's Late-Breaking Readout Roundtable program on Thursday, November 11, 2021, at 11:35 a.m. Eastern Time in Boston, Massachusetts. During the company's 30-minute presentation, Cortexyme's chief medical officer Michael Detke, MD, PhD, and GAIN Trial lead investigator Marwan Sabbagh, MD, FAAN, will provide additional GAIN Trial top-line results and analysis.

CTAD 2021 Late-Breaking Readout Roundtable Details

Title: Top-line Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer's Disease.

1Cortexyme - South San Francisco, CA (USA), 2Barrow Neurological Institute, Dignity Health/St. Joseph's Hospital and Medical Center - Phoenix, AZ (USA), 3UCSF - San Francisco, CA (USA), 4Innovative Analytics - Portage, MI (USA), 5Datafy Clinical R&D - Portage, MI (USA), 6Pentara Corporation - Millcreek, UT (USA), 7Forsyth Institute - Cambridge, MA (USA)

About Cortexyme

Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Cortexyme's lead program targets a specific, infectious pathogen called P. gingivalis found in the brain of Alzheimer's patients and other organs and tied to degeneration and inflammation in humans and animal models. The company's causation evidence for Alzheimer's disease and the mechanism of its novel therapeutic has been independently replicated and confirmed by multiple laboratories around the world, as well as published in peer-reviewed scientific journals. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.

These press releases may also interest you

at 13:39
Today, the U.S. Food and Drug Administration, in coordination with the Centers for Disease Control and Prevention (CDC), released federal data from the 2022 National Youth Tobacco Survey (NYTS) on e-cigarette use among U.S. youth. The findings,...

at 13:26
Select Medical today announced it plans to open a third inpatient rehabilitation hospital in Central Pennsylvania to serve the expanding needs of the West Shore region.  The new freestanding hospital, in partnership with UPMC, will feature 35 private...

at 13:24
OSF HealthCare and US HealthVest have signed a letter of intent to form a joint venture to build a behavioral health facility in Peoria, Illinois. Together they will develop and construct what will be the largest behavioral hospital focused on adults...

at 13:09
The Honourable Carolyn Bennett, Minister of Mental Health and Addictions and Associate Minister of Health, will announce funding to support the mental wellness of young people. Minister Bennett will be joined by representatives from Kids Help Phone....

at 13:05
To maximize patient and customer reach with our best-in-class imaging technology, Samsung has made the decision to increase its investment in the ultrasound business in North America. From investing in new product introductions featuring Samsung...

at 13:05
The "Endoscopic Imaging Systems Market - A Global and Regional Analysis: Focus on Product Type, Regional Analysis, and Country-Wise Analysis - Analysis and Forecast, 2022-2030" report has been added to ResearchAndMarkets.com's offering. The global...

News published on 4 november 2021 at 08:10 and distributed by: